Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Digital health tools

Topic: Amyloid, tau and blood-test diagnosis

Background Alzheimer's is a disease for which there is no cure. Diagnosing Alzheimer's disease (AD) early facilitates family planning and cost control. The purpose of this study is to predict the presence of AD using socio-demographic, clinical, and magnetic resonance imaging (MRI) data. Early detection of AD enables family planning and may reduce costs by delaying long-term care. Accurate, non-imagery methods also reduce patient costs. The Open Access Series of Imaging Studies (OASIS-1) cross-sectional MRI data were analyzed. A gradient boosted machine (GBM) predicted the presence of AD as a function of gender, age, education, socioeconomic status (SES), and a mini-mental state exam (MMSE). A residual network with 50 layers (ResNet-50) predicted the clinical dementia rating (CDR) presence and severity from MRI's (multi-class classification). The GBM achieved a mean 91.3% prediction accuracy (10-fold stratified cross validation) for dichotomous CDR using socio-demographic and MMSE variables. MMSE was the most important feature. ResNet-50 using image generation techniques based on an 80% training set resulted in 98.99% three class prediction accuracy on 4139 images (20% validation set) at Epoch 133 and nearly perfect multi-class predication accuracy on the training set (99.34%). Machine learning methods classify AD with high accuracy. GBM models may help provide initial detection based on non-imagery analysis, while ResNet-50 network models might help identify AD patients automatically prior to provider review.

Key findings

Why it matters

Machine learning methods classified Alzheimer's disease with high accuracy using socio-demographic, clinical and MRI data, with the MMSE being the most important feature. This is about improving detection and diagnosis, not about treating, curing or preventing the disease.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 49 of the 96 points it could be judged on, which is 51 of 100. Total 51 of 100.49 of the 96 points we could judge = 51 of 100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Brain sciences)
Journal's citation record 1 / 4 Brain Sciences: journal h-index 115 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 158 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 17.6 citations a year over 9 year(s) since 2019
Impact for its field and year 4 / 6 Cited 9.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 3 / 4 Cited 62 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Christopher Fulton holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 United States Air Force: institution h-index 273 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31443556)
Free to read 2 / 2 Free to read
Points 49 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100.
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Fulton, L. V., Dolezel, D., Harrop, J., Yan, Y., & Fulton, C. P. (2019). Classification of Alzheimer's Disease with and without Imagery using Gradient Boosted Machines and ResNet-50. Brain sciences. https://doi.org/10.3390/brainsci9090212

Vancouver

Fulton LV, Dolezel D, Harrop J, Yan Y, Fulton CP. Classification of Alzheimer's Disease with and without Imagery using Gradient Boosted Machines and ResNet-50. Brain sciences. 2019. doi:10.3390/brainsci9090212. PMID: 31443556.

BibTeX

@article{fulton2019-31443556,
  author  = {Fulton, L. V. and Dolezel, D. and Harrop, J. and Yan, Y. and Fulton, C. P.},
  title   = {{Classification of Alzheimer's Disease with and without Imagery using Gradient Boosted Machines and ResNet-50}},
  journal = {Brain sciences},
  year    = {2019},
  doi     = {10.3390/brainsci9090212},
  pmid    = {31443556},
  url     = {https://doi.org/10.3390/brainsci9090212}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Digital health tools

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Digital health tools

See all studies in Digital health tools →